抗逆转录病毒治疗启动与HIV感染者内脏及皮下脂肪组织密度降低相关
本研究为前瞻性随机临床试验,纳入228例初治HIV感染者,随机接受替诺福韦-恩曲他滨联合阿扎那韦/利托那韦、达芦那韦/利托那韦或雷特格韦治疗。96周内所有组别皮下和内脏脂肪组织CT密度均显著降低,且第96周较低脂肪密度与更高炎症、血脂紊乱和胰岛素抵抗指标相关。
要点
- ART启动后96周内皮下和内脏脂肪CT密度均显著降低。
- 较低脂肪密度与更高炎症、血脂异常和胰岛素抵抗相关。
- 脂肪密度变化对健康的影响独立于脂肪面积。
核心结论
- 病毒学抑制后,较低的皮下和内脏脂肪密度与更严重的全身炎症、血脂紊乱和胰岛素抵抗相关,且独立于脂肪面积。
研究设计与样本
- 前瞻性随机临床试验,纳入228例初治HIV感染者,随机接受替诺福韦-恩曲他滨联合阿扎那韦/利托那韦、达芦那韦/利托那韦或雷特格韦治疗,通过L4-L5腹部CT测量脂肪面积和密度。
主要发现
- 96周内所有治疗组皮下和内脏脂肪组织CT密度(Hounsfield单位)均显著降低。
- 第96周较低的皮下和内脏脂肪密度与更高HDL胆固醇和脂联素水平相关(r=0.19-0.30)。
- 第96周较低的皮下和内脏脂肪密度与更低白介素6、非HDL胆固醇、甘油三酯、瘦素和HOMA-IR水平相关(r=-0.23至-0.68)。
临床怎么用
- 监测ART启动后脂肪组织密度变化可能有助于识别炎症和代谢紊乱风险较高的HIV感染者。
局限性
- 研究对象以男性(89%)和白人非西班牙裔(44%)为主,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adipose tissue (AT) alterations are common in people living with human immunodeficiency virus (PLWH). Decreases in AT density suggest disrupted adipocyte function/hypertrophy. We assessed changes in AT density after antiretroviral therapy (ART) initiation and associations with immunometabolic parameters. METHODS: In a prospective randomized clinical trial of ART initiation, L4-L5 abdominal CT scans measured subcutaneous AT (SAT) and visceral AT (VAT) area and density in treatment-naive PLWH randomized to tenofovir-emtricitabine plus ritonavir-boosted atazanavir, ritonavir-boosted darunavir, or raltegravir. Linear regression models compared week 0 and week 96 levels, and 96-week changes, in SAT and VAT density (in Hounsfield units [HU]). Spearman correlations assessed relationships between AT density and immunometabolic parameters. RESULTS: Of the 228 participants, 89% were male and 44% were white non-Hispanic. Median age was 36 years, baseline HIV-1 RNA was 4.6 log10 copies/mL, and CD4+ T-cell count was 344 cells/μL. Over 96 weeks, SAT and VAT HU decreased significantly in all arms. Less dense week 96 SAT and VAT density correlated with higher high-density lipoprotein (HDL) cholesterol and adiponectin (r = 0.19-0.30) levels and lower interleukin 6, non-HDL cholesterol, triglyceride, leptin, and homeostatic model assessment of insulin resistance (r = -0.23 to -0.68) levels at week 96 after adjusting for baseline CD4+ T-cell count, HIV-1 RNA, and baseline AT area. CONCLUSIONS: Following virologic suppression, lower SAT and VAT density was associated with greater plasma measures of systemic inflammation, lipid disturbances, and insulin resistance independent of AT area, suggesting that changes in AT density with ART may lead to adverse health outcomes independent of AT quantity. CLINICAL TRIALS REGISTRATION: NCT00851799.
引用
- Debroy P, Lake JE, Moser C, et al. Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021. PMID: 32107532. doi:10.1093/cid/ciaa196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。